舒红兵

一、主要成果与研究方向

舒红兵，男，1967年1月生，中国科学院院士，发展中国家科学院院士，兰州兽医研究所家畜疫病病原生物学研究中心首席科学家。先后担任多项国家科技部项目首席科学家、国家自然科学基金委创新群体和基础科学中心等项目负责人。曾获《自然》杰出导师奖，国家自然科学二等奖两项，中国细胞生物学学会杰出成就奖等奖励与荣誉。在病毒免疫与炎症等领域取得了原创性、系统性成果，在国际重要期刊发表论文190余篇，被引用2万余次。已培养研究生70余人，博士后17人，其中34人晋升高级职称，9人入选国家级人才称号。

研究方向：研究重大动物疫病病原（非洲猪瘟、牛结节性皮肤病病毒）与重要人畜共患病病原（结核杆菌、布鲁氏菌）免疫及致病机制，研发相关mRNA疫苗。

邮箱：shuh@whu.edu.cn

二、教育及工作经历

1983.9-1987.6 兰州大学生物学系动物学专业，学士

1987.9-1990.6 中国医学科学院/中国协和医科大学

基础医学研究所细胞生物学研究室，硕士

1990.7-1992.8 美国密西根大学医学中心，研究助理

1992.9-1995.6 美国Emory大学细胞与发育生物学专业，博士

1995.7-1997.7 美国旧金山Tularik公司, 博士后

1997.8-1998.7 美国Magainin制药公司，Senior Scientist

1998.8-2005.8 美国犹太医学研究中心及科罗拉多大学医学院免疫学系，助理教授、副教授

2000.1-2004.12 北京大学生命科学学院，长江教授

2005.9-2013.12 武汉大学生命科学学院，院长

2013.8-2022.1 武汉大学，副校长

2005.9-至今   武汉大学生命科学学院，教授

2014.5-至今   武汉大学医学研究院，院长，教授

2022.11-至今  中国农业科学院兰州兽医研究所/兰州大学动物医学与生物安全学院，兼职PI

三、近三年发表论文

1．Hu MM, Shu HB* (2023). Mitochondrial DNA-triggered innate immune response: mechanisms and diseases. Cell Mol Immunol. 20(12):1403-1412

2．Liu R, Zeng LW, Li HF, Shi JG, Zhong B, Shu HB* & Shu Li* (2023). PD-1 signaling negatively regulates the common cytokine receptor γ chain via MARCH5-mediated ubiquitination and degradation to suppress anti-tumor immunity. Cell Res. 33(12):923–939

3．Cao LB, Ruan ZL, Yang YL, Zhang NC, Gao C, Cai CG, Zhang J, Hu MM*, Shu HB* (2023). Estrogen receptor α-mediated signaling inhibits type I interferon response to promote breast cancer. J Mol Cell Biol. 13:mjad047

4．Guo Y, Zhang XN, Su S, Ruan ZL, Hu MM*, Shu HB* (2023). β-adrenoreceptor-triggered PKA activation negatively regulates the innate antiviral response. Cell Mol Immunol. 20(2):175-188

5．Zhong B, Shu HB* (2022). MITA/STING-mediated antiviral immunity and autoimmunity: the evolution, mechanism, and intervention. Curr Opin Immunol. 78:102248

6．Su S^#, Hua D^#, Li JP^#, Zhang XN, Bai L, Cao LB, Guo Y, Zhang M, Dong JZ, Liang XW, Lan K, Hu MM*, Shu HB* (2022). Modulation of innate immune response to viruses including SARS-CoV-2 by progesterone. Signal Transduct Target Ther. 7(1):137

7．Feng L, Li C, Zeng LW, Gao D, Sun YH, Zhong L, Lin H, Shu HB*, Li S* (2022). MARCH3 negatively regulates IL-3-triggered inflammatory response by mediating K48-linked polyubiquitination and degradation of IL-3Rα. Signal Transduct Target Ther. 7(1):21

8．Lin H, Feng L, Cui KS, Zeng LW, Gao D, Zhang LX, Xu WH, Sun YH, Shu HB*, Li S* (2021). The membrane-associated E3 ubiquitin ligase MARCH3 downregulates the IL-6 receptor and suppresses colitis-associated carcinogenesis. Cell Mol Immunol. 18(12):2648-2659

9．Zhong L, Shu HB* (2021). Mitotic inactivation of the cGAS‒MITA/STING pathways. J Mol Cell Biol. 13(10):721-727

10．Li C, Feng L, Luo WW, Lei CQ, Li M, Shu HB* (2021). The RNA-binding protein LUC7L2 mediates MITA/STING intron retention to negatively regulate innate antiviral response. Cell Discov. 7(1):46

11．He WR, Cao LB, Yang YL, Hua D, Hu MM, Shu HB* (2021). VRK2 is involved in the innate antiviral response by promoting mitostress-induced mtDNA release. Cell Mol Immunol 18(5):1186-1196

12．Song ZM, Lin H, Yi XM, Guo W, Ming-Ming Hu, Shu HB* (2020). KAT5 acetylates cGAS to promote innate immune response to DNA virus. Proc Natl Acad Sci U S A. 117(35):21568-21575

13．Zhong L, Hu MM, Bian LJ, Liu Y, Chen Q and Shu HB* (2020). Phosphorylation of cGAS by CDK1 impairs self-DNA sensing in mitosis. Cell Discov. 28:6:26

14．Li M, Shu HB* (2020). Dephosphorylation of cGAS by PPP6C impairs its substrate binding activity and innate antiviral response. Protein Cell. 11(8):584-599

15．Liao Chen-Yang, Lei Cao-Qi, Shu HB* (2020). PCBP1 modulates the innate immune response by facilitating the binding of cGAS to DNA. Cell Mol Immunol. 18(10):2334-2343

16．Zhong X, Feng L, Zang R, Lei Cao-Qi, Yang Qing, Shu HB* (2020). ZFYVE1 negatively regulates MDA5- but not RIG-I-mediated innate antiviral response. PLoS Pathog. 16(4):e1008457

17．Zang R, Lian H, Zhong X, Yang Q*, Shu HB* (2020). ZCCHC3 modulates TLR3-mediated signaling by promoting recruitment of TRIF to TLR3. J Mol Cell Biol. 12(4):251-262

18．Yang Q, Shu HB* (2020). Deciphering the pathways to antiviral innate immunity and inflammation. Adv Immunol. 145:1-36

19．Hu MM, Shu HB*(2020). Innate Immune Response to Cytoplasmic DNA: Mechanisms and Diseases. Annu Rev Immunol. 38:79-98